NCT00370890 - A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

September 4, 2006

Primary Completion Date

October 26, 2021

Study Completion Date

October 26, 2021

Conditions

Nasopharyngeal Cancer

Interventions

DRUG

Adjuvant chemotherapy (gemcitabine and cisplatin)

Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles

Trial Locations (6)

Unknown

Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong

Department of Clinical Oncology, Queen Mary Hospital, Hong Kong

Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong

Department of Oncology, Princess Margaret Hospital, Hong Kong

All Listed Sponsors

collaborator

Hong Kong Nasopharyngeal Cancer Study Group Limited

OTHER

lead

Chinese University of Hong Kong

OTHER